Roivant Sciences

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline.[3] Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

History

Vivek Ramaswamy founded Roivant in 2014.[4] Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas.[5] This strategy expanded to include developing earlier stage drug candidates and platform technologies. Roivant is a parent company to over a dozen subsidiaries ranging from Immunovant, a majority-owned public company focused on autoimmune diseases, to privately held Dermavant Sciences, a commercial-stage company

Subsidiaries and former subsidiaries

As of April 2020, the company's subsidiaries include:

The following subsidiaries were previously a part of Roivant, but were included as part of a strategic transaction with Sumitomo Dainippon Pharma which closed in December 2019:[35]

Roivant is a major shareholder of Datavant, which was co-founded with Travis May to link disparate healthcare datasets.[43] In October 2020, Datavant announced it raised funds from Roivant alongside Transformation Capital, Johnson & Johnson, and Cigna.[44]

In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries.[45]

In March 2020, Roivant announced it is developing gimsilumab, an anti-granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19.[46] In April 2020, Roivant started the administration of gimsilumab to COVID-19 patients in the United States.[47]

Affivant

Covant

Datavant

Genevant, created to work on RNA-based therapeutics[32]

Hemovant

Immunovant, launched in July 2018 to develop therapies for autoimmune diseases, with lead candidate IMVT-1401 being developed for the treatment of myasthenia gravis, Graves' ophthalmopathy and warm antibody autoimmune hemolytic anemia[33]

Kinevant, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases

Lokavant, which is focused on improving clinical trial monitoring[34]

Priovant

Psivant

Altavant Sciences, which is developing a treatment for pulmonary arterial hypertension[36]

Dermavant, focused on developing therapeutics in medical dermatology, with lead candidate tapinarof in development for the treatment of psoriasis and atopic dermatitis[37] Organon & Co. agreed to acquire Dermavant in a deal worth up to $1.2 billion, including a $175 million upfront payment.[38]

Enzyvant Therapeutics, which is focused on developing therapies for rare enzyme deficiencies[39]

Myovant Sciences, founded in partnership with Takeda Pharmaceutical Company to develop medicines for women's health and prostate cancer[40]

type	Public
traded as	nasdaq: ROIV S&P 400 component
founded	April 7, 2014
founder	Vivek Ramaswamy
key people	Matt Gline (CEO)
hq location	151 West 42nd Street New York, NY 10036 U.S.
industry	Pharmaceuticals
num employees	908 (2024)
revenue	US$125 million (2024)
operating income	US$4.24 billion (2024)
net income	US$4.35 billion (2024)
assets	US$7.22 billion (2024)
equity	US$6.45 billion (2024)
owner	Vivek Ramaswamy (10.5%)
website	roivant.com
footnotes	Financials as of 31 March 2024.‡R1R‡‡R2R‡

History

Subsidiaries and former subsidiaries

Funding

External links

References